Balance Sheet VYNE Therapeutics Inc.

Equities

VYNE

US92941V3087

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-24 pm EST			5-day change	1st Jan Change
2.760 ^USD	+3.37%		+2.22%	-17.61%

Jan. 06	VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo	CI
Dec. 23	VYNE Therapeutics Reports 'Positive' Phase 1a Results for VYN202 Inhibitor	MT

8ec6de66.5-6983UN8NM9XPvIQWuGy2SWLtBjygo5fP53PEiaq2Q.jpzZkC9_p7UFEbSgODLxgwPedoMFpE1fCc4zUy387giBiY6yF0bdlUgOiA

Published financial data: VYNE THERAPEUTICS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	443K	20.99M	14.76M	477K	424K
Total Revenues	443K	20.99M	14.76M	477K	424K
Cost of Goods Sold, Total	-	1.39M	3.35M	-	-
Gross Profit	443K	19.6M	11.41M	477K	424K
Selling General & Admin Expenses, Total	45.91M	77.14M	54.48M	16.39M	13.38M
R&D Expenses	50.41M	39.73M	24.96M	18.38M	16.31M
Other Operating Expenses, Total	96.32M	117M	79.44M	34.77M	29.68M
Operating Income	-95.87M	-97.28M	-68.03M	-34.3M	-29.26M
Interest Expense, Total	-921K	-4.39M	-5.61M	-	-
Interest And Investment Income	589K	-	-	-	1.39M
Net Interest Expenses	-332K	-4.39M	-5.61M	-	1.39M
Currency Exchange Gains (Loss)	-213K	-	-	-	-
Other Non Operating Income (Expenses)	-19K	968K	-135K	363K	-
EBT, Excl. Unusual Items	-96.44M	-101M	-73.78M	-33.93M	-27.87M
Merger & Related Restructuring Charges	-	-16.2M	-	-	-
Impairment of Goodwill	-	-4.54M	-	-	-
Gain (Loss) On Sale Of Investments	1.08M	142K	-	-	-
In Process R&D Expenses	-	-49.8M	-	-	-
Other Unusual Items	-	-84.73M	-	-	-
EBT, Incl. Unusual Items	-95.35M	-256M	-73.78M	-33.93M	-27.87M
Income Tax Expense	-176K	-258K	-448K	13K	-
Earnings From Continuing Operations	-95.18M	-256M	-73.33M	-33.94M	-27.87M
Earnings Of Discontinued Operations	-	-	-	10.74M	-580K
Net Income to Company	-95.18M	-256M	-73.33M	-23.21M	-28.45M
Net Income - (IS)	-95.18M	-256M	-73.33M	-23.21M	-28.45M
Preferred Dividend and Other Adjustments	-	-	-	-	149K
Net Income to Common Incl Extra Items	-95.18M	-256M	-73.33M	-23.21M	-28.6M
Net Income to Common Excl. Extra Items	-95.18M	-256M	-73.33M	-33.94M	-28.02M
Per Share Items
Net EPS - Basic	-119.61	-141.9	-25.64	-7.28	-2.78
Basic EPS - Continuing Operations	-119.61	-141.9	-25.64	-10.65	-2.73
Basic Weighted Average Shares Outstanding	796K	1.8M	2.86M	3.19M	10.27M
Net EPS - Diluted	-119.61	-141.9	-25.64	-7.28	-2.78
Diluted EPS - Continuing Operations	-119.61	-141.9	-25.64	-10.65	-2.73
Diluted Weighted Average Shares Outstanding	796K	1.8M	2.86M	3.19M	10.27M
Normalized Basic EPS	-75.75	-34.94	-16.13	-6.66	-1.7
Normalized Diluted EPS	-75.75	-34.94	-16.13	-6.66	-1.7
Supplemental Items
EBITDA	-95.52M	-96.93M	-67.92M	-34.22M	-29.19M
EBITA	-95.87M	-97.28M	-68.03M	-34.3M	-29.26M
EBIT	-95.87M	-97.28M	-68.03M	-34.3M	-29.26M
EBITDAR	-94.63M	-95.58M	-67.13M	-33.93M	-29.08M
Total Revenues (As Reported)	-	20.99M	14.76M	477K	424K
Effective Tax Rate - (Ratio)	0.18	0.1	0.61	-0.04	-
Current Domestic Taxes	-	-253K	-448K	13K	-121K
Current Foreign Taxes	-	-	-	-	121K
Total Current Taxes	-	-253K	-448K	13K	0
Normalized Net Income	-60.27M	-62.94M	-46.11M	-21.21M	-17.42M
Interest on Long-Term Debt	921K	4.4M	5.6M	-	-
Non-Cash Pension Expense	719K	8.5M	-	-	-
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	51.2M	43.53M	24.96M	18.38M	16.31M
Net Rental Expense, Total	889K	1.35M	791K	297K	102K
Imputed Operating Lease Interest Expense	-	1.37M	2.02M	-	-
Imputed Operating Lease Depreciation	-	-19.23K	-1.23M	-	-
Stock-Based Comp., COGS (Total)	-	-	-	-	-
Stock-Based Comp., R&D Exp. (Total)	1.56M	4.75M	1.71M	1.23M	534K
Stock-Based Comp., SG&A Exp. (Total)	3.33M	13.35M	6.37M	3.42M	2.77M
Total Stock-Based Compensation	4.9M	18.1M	8.08M	4.65M	3.3M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	43.76M	57.56M	42.25M	30.91M	30.62M
Short Term Investments	28.35M	1.03M	-	-	62.63M
Total Cash And Short Term Investments	72.11M	58.59M	42.25M	30.91M	93.25M
Accounts Receivable, Total	135K	15.82M	7.58M	173K	-
Other Receivables	-	-	-	5M	-
Total Receivables	135K	15.82M	7.58M	5.17M	-
Inventory	1.36M	7.4M	7.29M	-	-
Prepaid Expenses	1.04M	4.59M	5.12M	2.13M	2.66M
Restricted Cash	825K	855K	605K	67K	54K
Other Current Assets, Total	953K	-	338K	-	-
Total Current Assets	76.41M	87.26M	63.19M	38.28M	95.96M
Gross Property Plant And Equipment	5.81M	2.58M	905K	-	-
Accumulated Depreciation	-1.23M	-443K	-551K	-	-
Net Property Plant And Equipment	4.58M	2.14M	354K	-	207K
Long-term Investments	-	-	-	-	-
Other Long-Term Assets, Total	166K	4.34M	3.51M	2.48M	1.52M
Total Assets	81.16M	93.74M	67.05M	40.76M	97.68M
Liabilities
Accounts Payable, Total	19.35M	4.78M	6.51M	2.39M	1.66M
Accrued Expenses, Total	8.61M	10.01M	6.05M	4.26M	3.51M
Current Portion of Long-Term Debt	-	-	-	-	-
Current Portion of Leases	1.09M	757K	349K	-	115K
Unearned Revenue Current, Total	-	5.8M	5.5M	-	-
Other Current Liabilities	270K	104K	-	2.7M	2.25M
Total Current Liabilities	29.33M	21.45M	18.41M	9.34M	7.54M
Long-Term Debt	32.72M	33.17M	-	-	-
Long-Term Leases	653K	853K	-	-	99K
Pension & Other Post Retirement Benefits	424K	312K	-	-	-
Other Non Current Liabilities	456K	457K	-	-	1.31M
Total Liabilities	63.58M	56.25M	18.41M	9.34M	8.95M
Preferred Stock Convertible	-	-	-	211K	-
Total Preferred Equity	-	-	-	211K	-
Common Stock, Total	2.66M	4K	5K	-	1K
Additional Paid In Capital	325M	604M	688M	694M	780M
Retained Earnings	-311M	-566M	-640M	-663M	-691M
Comprehensive Income and Other	5K	-	-	-	26K
Total Common Equity	17.58M	37.49M	48.64M	31.2M	88.74M
Total Equity	17.58M	37.49M	48.64M	31.41M	88.74M
Total Liabilities And Equity	81.16M	93.74M	67.05M	40.76M	97.68M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	61.63M	2.85M	3.12M	3.26M	14.1M
ECS Total Common Shares Outstanding	61.58M	2.4M	2.98M	3.23M	14.1M
Book Value / Share	0.29	15.62	16.34	9.66	6.29
Tangible Book Value	17.58M	37.49M	48.64M	31.2M	88.74M
Tangible Book Value Per Share	0.29	15.62	16.34	9.66	6.29
Total Debt	34.47M	34.78M	349K	0	214K
Net Debt	-37.64M	-23.81M	-41.9M	-30.91M	-93.04M
Debt Equivalent of Unfunded Proj. Benefit Obligation	424K	312K	206K	206K	-
Debt Equivalent Oper. Leases	7.11M	10.81M	6.33M	2.38M	816K
Account Code - Inventory Valuation	5	5	5	5	3
Inventories - Raw Materials, Total	500K	4.04M	3.3M	-	-
Inventories - Work In Process, Total	-	662K	33K	-	-
Inventories - Finished Goods, Total	856K	2.7M	3.96M	-	-
Machinery, Total	3.06M	939K	846K	-	-
Full Time Employees	40	106	28	12	10
Part Time Employees	-	-	-	-	-

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	-95.18M	-256M	-73.33M	-23.21M	-28.45M
Depreciation & Amortization - CF	350K	341K	109K	72K	-
Depreciation & Amortization, Total	350K	341K	109K	72K	-
(Gain) Loss From Sale Of Asset	18K	2.1M	93K	282K	-
(Gain) Loss on Sale of Investments - (CF)	-357K	-142K	-	-	-255K
Asset Writedown & Restructuring Costs	-	54.34M	-	-	-
Stock-Based Compensation (CF)	4.9M	18.1M	8.08M	4.3M	3.3M
Net Cash From Discontinued Operations	-	-	-	-12.92M	-
Other Operating Activities, Total	197K	84.07M	3.9M	-	1K
Change In Accounts Receivable	373K	-17.14M	7.71M	11.21M	405K
Change In Inventories	-1.36M	-6.05M	113K	97K	-
Change In Accounts Payable	18.05M	-12.98M	-2.68M	-8.68M	-559K
Change in Other Net Operating Assets	-389K	-4.17M	-371K	-349K	214K
Cash from Operations	-73.39M	-137M	-56.37M	-29.2M	-25.34M
Capital Expenditure	-1.06M	-113K	-	-	-
Sale of Property, Plant, and Equipment	40K	-	-	-	-
Cash Acquisitions	-	38.64M	-	-	-
Investment in Marketable and Equity Securities, Total	42.89M	50.58M	1.03M	-	-62.35M
Other Investing Activities, Total	-	-	-	15.67M	5M
Cash from Investing	41.87M	89.11M	1.03M	15.67M	-57.35M
Long-Term Debt Issued, Total	35M	-	-	-	-
Total Debt Issued	35M	-	-	-	-
Long-Term Debt Repaid, Total	-	-	-36.43M	-	-
Total Debt Repaid	-	-	-36.43M	-	-
Issuance of Common Stock	14.08M	61.95M	76.5M	1.47M	82.82M
Repurchase of Common Stock	-32K	-141K	-294K	-	-67K
Issuance of Preferred Stock	-	-	-	211K	-
Repurchase of Preferred Stock	-	-	-	-	-360K
Other Financing Activities, Total	-1.1M	-	-	-28K	-
Cash from Financing	47.95M	61.81M	39.78M	1.65M	82.39M
Foreign Exchange Rate Adjustments	41K	1K	-	-	-
Net Change in Cash	16.47M	13.83M	-15.56M	-11.88M	-301K
Supplemental Items
Cash Interest Paid	802K	3.94M	2.38M	-	-
Cash Income Tax Paid (Refund)	-	-	-	-	-
Levered Free Cash Flow	-40.27M	-77.11M	-33.05M	-11.86M	-12.25M
Unlevered Free Cash Flow	-39.69M	-74.37M	-29.54M	-11.86M	-12.25M
Change In Net Working Capital	-16.04M	31.9M	-4.79M	-4.85M	-2.74M
Net Debt Issued / Repaid	35M	-	-36.43M	-	-

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	-64.82	-69.52	-52.89	-39.77	-26.42
Return on Total Capital	-83.09	-97.81	-70.13	-53.32	-30.39
Return On Equity %	-173.43	-928.19	-170.28	-84.81	-46.4
Return on Common Equity	-173.43	-928.19	-170.28	-85.03	-46.73
Margin Analysis
Gross Profit Margin %	100	93.37	77.31	100	100
SG&A Margin	10.36K	367.47	369.24	3.44K	3.15K
EBITDA Margin %	-21.56K	-461.74	-460.34	-7.17K	-6.88K
EBITA Margin %	-21.64K	-463.37	-461.08	-7.19K	-6.9K
EBIT Margin %	-21.64K	-463.37	-461.08	-7.19K	-6.9K
Income From Continuing Operations Margin %	-21.48K	-1.22K	-496.98	-7.12K	-6.57K
Net Income Margin %	-21.48K	-1.22K	-496.98	-4.87K	-6.71K
Net Avail. For Common Margin %	-21.48K	-1.22K	-496.98	-7.12K	-6.61K
Normalized Net Income Margin	-13.61K	-299.79	-312.51	-4.45K	-4.11K
Levered Free Cash Flow Margin	-9.09K	-367.33	-224	-2.49K	-2.89K
Unlevered Free Cash Flow Margin	-8.96K	-354.26	-200.24	-2.49K	-2.89K
Asset Turnover
Asset Turnover	0	0.24	0.18	0.01	0.01
Fixed Assets Turnover	0.13	6.25	11.84	-	-
Receivables Turnover (Average Receivables)	0.74	2.63	1.26	0.12	-
Inventory Turnover (Average Inventory)	-	0.32	0.46	-	-
Short Term Liquidity
Current Ratio	2.61	4.07	3.43	4.1	12.73
Quick Ratio	2.46	3.47	2.71	3.86	12.37
Operating Cash Flow to Current Liabilities	-2.5	-6.39	-3.06	-3.12	-3.36
Days Sales Outstanding (Average Receivables)	494.77	139.07	289.45	2.97K	-
Days Outstanding Inventory (Average Inventory)	-	1.15K	801.03	-	-
Average Days Payable Outstanding	-	593.57	636.92	-	-
Cash Conversion Cycle (Average Days)	-	697.14	453.56	-	-
Long Term Solvency
Total Debt/Equity	196.13	92.77	0.72	-	0.24
Total Debt / Total Capital	66.23	48.13	0.71	-	0.24
LT Debt/Equity	189.92	90.76	-	-	0.11
Long-Term Debt / Total Capital	64.13	47.08	-	-	0.11
Total Liabilities / Total Assets	78.34	60	27.46	22.93	9.16
EBIT / Interest Expense	-104.1	-22.16	-12.13	-	-
EBITDA / Interest Expense	-102.75	-21.77	-11.97	-	-
(EBITDA - Capex) / Interest Expense	-103.9	-21.8	-11.97	-	-
Total Debt / EBITDA	-0.36	-0.36	-0.01	-	-0.01
Net Debt / EBITDA	0.4	0.25	0.62	0.9	3.2
Total Debt / (EBITDA - Capex)	-0.36	-0.36	-0.01	-	-0.01
Net Debt / (EBITDA - Capex)	0.39	0.25	0.62	0.9	3.2
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-87.68	4.64K	-29.71	-48.76	-11.11
Gross Profit, 1 Yr. Growth %	-87.68	4.32K	-41.8	-48.76	-11.11
EBITDA, 1 Yr. Growth %	28.09	1.48	-39.96	-11.8	-14.72
EBITA, 1 Yr. Growth %	28.02	1.46	-40.05	-11.86	-14.69
EBIT, 1 Yr. Growth %	28.02	1.46	-40.05	-11.86	-14.69
Earnings From Cont. Operations, 1 Yr. Growth %	28.34	168.52	-71.31	-23.22	-17.89
Net Income, 1 Yr. Growth %	28.34	168.52	-71.31	-68.35	22.58
Normalized Net Income, 1 Yr. Growth %	29.2	5.21	-36.89	-24.01	-17.86
Diluted EPS Before Extra, 1 Yr. Growth %	-2.2	-29.72	-81.93	-31.1	-74.4
Accounts Receivable, 1 Yr. Growth %	-87.34	11.62K	-52.06	-97.72	-
Inventory, 1 Yr. Growth %	-	446.02	-1.53	-	-
Net Property, Plant and Equip., 1 Yr. Growth %	104.88	-53.31	-83.44	-	-
Total Assets, 1 Yr. Growth %	-21.76	15.5	-28.48	-39.21	139.67
Tangible Book Value, 1 Yr. Growth %	-80.93	113.33	29.72	-35.85	184.39
Common Equity, 1 Yr. Growth %